MRK Merck & Co Inc

  1. Stocks
  2. Healthcare
  3. NYSE: MRK

Price (delayed)

$115.48

Market cap

$285.22B

P/E Ratio

32.35

Dividend/share

$3.36

EPS

$3.57

Enterprise value

$329.01B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 66
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 74

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
The revenue has grown by 2.9% YoY
The P/E is 82% higher than the last 4 quarters average of 17.8 but 53% lower than the 5-year quarterly average of 69.0
The net income has dropped by 51% since the previous quarter and by 49% year-on-year
The EPS has plunged by 51% from the previous quarter and by 48% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.merck.com/
Peers: PFE JNJ LLY BMY

Key stats

What are the main financial stats of MRK

MRK stock price

How has the Merck stock price performed over time
Intraday
1.41%
1 week
0.5%
1 month
-5.66%
1 year
46.07%
YTD
9.71%
QTD
-4%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$65.77B
Gross profit
$48.61B
Operating income
$11.96B
Net income
$8.94B
Gross margin
73.9%
Net margin
13.6%
MRK's net margin has dropped by 52% since the previous quarter and by 50% year-on-year
The net income has dropped by 51% since the previous quarter and by 49% year-on-year
Merck's operating income has decreased by 44% from the previous quarter and by 41% YoY
Merck's operating margin has decreased by 44% QoQ and by 42% YoY

Price vs fundamentals

How does MRK's price correlate with its fundamentals

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
MRK P/E details
P/E
32.35
P/B
6.22
P/S
4.34
EV/EBIT
25.01
EV/EBITDA
16.96
EV/Sales
5
The P/E is 82% higher than the last 4 quarters average of 17.8 but 53% lower than the 5-year quarterly average of 69.0
The EPS has plunged by 51% from the previous quarter and by 48% YoY
The price to book (P/B) is 27% higher than the last 4 quarters average of 4.9 and 7% higher than the 5-year quarterly average of 5.8
Merck's equity has decreased by 13% from the previous quarter and by 5% YoY
MRK's P/S is 17% above its last 4 quarters average of 3.7
The revenue has grown by 2.9% YoY

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 54% YoY and by 52% QoQ
Merck's ROE has plunged by 53% YoY and by 51% from the previous quarter
The ROIC fell by 49% YoY and by 44% QoQ
The ROS has contracted by 42% from the previous quarter and by 40% YoY

Dividends

What is MRK's dividend history
Dividend details
DPS
$3.36
Dividend yield
2.91%
Payout ratio
94.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Merck financials performed over time
The total assets is 56% more than the total liabilities
MRK's quick ratio is down by 29% since the previous quarter and by 18% year-on-year
Merck's total liabilities has increased by 24% YoY
MRK's debt is 7% greater than its equity
The debt to equity has grown by 49% YoY and by 14% from the previous quarter
MRK's debt is up by 41% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.